Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2000

01-03-2000 | ORIGINAL ARTICLE

Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide

Authors: James L. Flowers, Susan M. Ludeman, Michael P. Gamcsik, O. Michael Colvin, Kai-Liu Shao, Jila H. Boal, James B. Springer, David J. Adams

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2000

Login to get access
Metadata
Title
Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide
Authors
James L. Flowers
Susan M. Ludeman
Michael P. Gamcsik
O. Michael Colvin
Kai-Liu Shao
Jila H. Boal
James B. Springer
David J. Adams
Publication date
01-03-2000
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2000
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050049

Other articles of this Issue 4/2000

Cancer Chemotherapy and Pharmacology 4/2000 Go to the issue

ORIGINAL ARTICLE

Human intestinal es nucleoside transporter: molecular characterization and nucleoside inhibitory profiles

ORIGINAL ARTICLE

Ara-C affects formation of cancer cell DNA synthesome replication intermediates

ORIGINAL ARTICLE

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

ORIGINAL ARTICLE

Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer

ORIGINAL ARTICLE

Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats

ORIGINAL ARTICLE

Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits